Paradigm Biopharmaceuticals (ASX:PAR) Treasury Stock: A$0.00 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
27 GF Score
Price A$0.18
! 5 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals Treasury Stock?

Paradigm Biopharmaceuticals ASX:PAR +2.94% 27 Treasury Stock is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 27/100. The stock has 5 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Paradigm Biopharmaceuticals's treasury stock for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Paradigm Biopharmaceuticals Treasury Stock Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals Treasury Stock Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PAR
27GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Paradigm Biopharmaceuticals Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of A$0.00 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a Treasury Stock of A$0.00 Mil as of Dec. 2025. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Paradigm Biopharmaceuticals and its competitors.
Is Paradigm Biopharmaceuticals' Treasury Stock too high?
Paradigm Biopharmaceuticals' current Treasury Stock is A$0.00 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' Treasury Stock compare to VRTX and REGN?
Paradigm Biopharmaceuticals' Treasury Stock of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Paradigm Biopharmaceuticals and its competitors. Paradigm Biopharmaceuticals's current Treasury Stock is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current Treasury Stock of A$0.00 Mil. The current Treasury Stock is A$0.00 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current Treasury Stock is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
27GF Score

Get the complete analysis for ASX:PAR

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price